After recruiting an AstraZeneca vet as CEO to head a new team and raising $139M cash, little Olema appears to be ready to launch … something
Sean Bohen is managing his re-entry into the R&D world in style. And he’s swerving straight into the fast lane.
A couple of weeks after we chatted about the end of his sabbatical following his departure from AstraZeneca as CMO and his new job as CEO of Olema Oncology, Bohen took the wraps off of an $85 million investment round that puts him in league with some of the highest profile investors in the field.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.